The objective of this project is to provide services, personnel, equipment and facilities as required to perform analysis of bulk drug substances and formulated drug products under cgmp conditions.…
Ended Awarded Last action
- Contract number
- 75N91020F00004
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $25,686
Award facts
- Contract value 100% obligated
- $25,685.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$789 | |
| Original award | $26,475 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to SRI International, a non-profit research and development institute. The objective of the $25,685.62 contract is to provide services, personnel, equipment, and facilities to perform analysis of bulk drug substances and formulated drug products under current good manufacturing practice (cGMP) conditions. The contract has a period of performance from July 15, 2020 to December 31, 2020 and is not set aside for small businesses. This contract is part of the larger "NIH Analysis of Anti-Cancer Chemicals 2017-2022" indefinite delivery vehicle, through which SRI International has demonstrated extensive capabilities in delivering advanced research and development services to federal agencies.
Description
The objective of this project is to provide services, personnel, equipment and facilities as required to perform analysis of bulk drug substances and formulated drug products under cgmp conditions. POP is 7/15/2020-12/31/2020
Quick answers
Who was awarded contract 75N91020F00004?
75N91020F00004 was awarded to Sri International by National Cancer Institute (National Institutes of Health) on July 15, 2020.
How much is contract 75N91020F00004 worth?
The government has obligated $25,686 on 75N91020F00004.
Is contract 75N91020F00004 an order under another contract?
Yes. 75N91020F00004 is a delivery order under HHSN261201700014I, an indefinite delivery contract, on NIH Analysis of Anti-Cancer Chemicals 2017-2022.
Was contract 75N91020F00004 competed?
The extent of competition for 75N91020F00004 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award